Stakeholder Guide

Stakeholder Guide

Find out more about the sponsors and exhibitors of the AMR Conference 2023

AUROBAC THERAPEUTICS is a biopharmaceutical company founded as a joint venture by Boehringer Ingelheim, Evotec and bioMérieux, to create the next generation of products to fight difficult-to-treat infectious diseases and AntiMicrobial Resistance (AMR). Our goal is to develop precision medicines, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics. We will cover the entire value chain of projects from R&D, including clinical development, to registration and commercialization. 

AUROBAC is currently seeking to strengthen its product portfolio and is particularly interested in in-licensing/co-developing innovative products developed to fight bacterial infections & AMR. 


Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. The company has successfully developed and launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, Basilea has preclinical anti-infective assets in its portfolio and is listed on the SIX Swiss Exchange (SIX: BSLN). More on

BioVersys AG focuses on life threatening infectious diseases. As a privately owned clinical stage Swiss pharmaceutical company working on research & development of small molecules acting on novel bacterial targets, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2-ready), and tuberculosis (BVL-GSK098, Phase 2a) in collaboration with GSK and a consortium of the University of Lille.

Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing new antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing early stage through phase II research of novel, pathogen-specific antibiotics, with afabicin, specifically targeting staphylococci spp., being the most clinically advanced for the treatment of Bone & Joint infections. As a result of highly selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota while meeting all four WHO 2020 innovativeness criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.

At the German Center for Infection Research (DZIF), about 500 researchers from 35 institutions throughout Germany jointly develop new approaches for the prevention, diagnosis and treatment of infectious diseases. The aim of this nationwide collaboration between universities, hospitals and research institutions is to translate research results into clinical practice quickly and effectively. With this, the DZIF paves the way for developing new vaccines, diagnostic agents and drugs to treat infections.


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere.

At the InfectoGnostics Research Campus, diagnostic methods are developed and combined to reliably detect infectious agents and antibiotic resistance and to better understand the host response. Connecting basic research, development and application at an early stage results in market-ready laboratory and point-of-care-tests for use in human and veterinary medicine as well as for environmental/water and food analysis. More than 30 partners from science, medicine and industry are working together on novel solutions for the rapid and cost-effective diagnosis of infectious diseases.

Further information can be found at: 

Youtube video: 


LEIBNIZ HEALTH TECHNOLOGIES: A Research Alliance of the Leibniz Association  

Providing technological solutions for unmet medical needs − this is the main focus of the 19 members of the interdisciplinary research alliance Leibniz Health Technologies. 

To battle antimicrobial resistances, 16 Leibniz institutes and 3 spin-off companies are cooperating in developing e.g. the “RamanBioAssay”, a photonics-based test to determine the efficacy of antibiotics (MIC) in less than 4 hours.  The alliance is also inventing therapeutic devices based on cold atmospheric plasma, which is a suitable technology for deactivating various types of microorganisms, including multi-resistant bacteria such as MRSA.

LifeArc is one of the UK’s largest independent medical research charities and a catalyst for innovation in the UK and globally. We work with some of the world’s leading thought leaders, life science organisations, scientists, charities, and medical institutions to accelerate discoveries into next generation diagnostics, therapies and cures for people who need it most.

The LifeArc Chronic Respiratory Infection Translational Challenge is our new £100m programme to accelerate scientific innovation for people living with bronchiectasis and cystic fibrosis. We’ll invest up to £100m by 2030 in collaborative programmes to develop new diagnostics, therapies and technologies to transform how chronic respiratory infections are detected, treated and managed. Our goal is to enable people with bronchiectasis and cystic fibrosis to live longer with improved quality of life by ending the vicious cycle of infection, exacerbation, and permanent lung damage 

We’ve joined The Cystic Fibrosis Trust and Medicines Discovery Catapult in a strategic partnership as part of the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate to address unmet patient needs by linking people with CF with leading experts across industry, academia and the NHS. Together, this cross-sector consortium is identifying and tackling drug discovery hurdles to accelerate the development of CF antimicrobials and infection diagnostics and the speed at which they can reach the people who need them.

Find out more about our exciting programme at:


Created in France by pioneers in rapid in vitro diagnostic tests, NG Biotech has leveraged the Lateral Flow Immunochromatography technology (LFIA) to become a leading expert in the field of rapid tests.

NG Biotech has developed a large range of Antimicrobial Resistance (AMR), Women’s Health and Infectious diagnostic tests.

It was the first company to develop and commercialize a rapid 5 lines multiplex LFIA test (NG-Test® CARBA-5) for the detection and differentiation the five most prevalent carbapenemases families (KPC, OXA-48-like, VIM, IMP et NDM) and their most clinically relevant variants in less than 15 minutes in a single cassette.

NG Biotech is also commercializing tests to detect ESBL resistance (NG-Test® CTX-M MULTI) and Colistin resistance (NG-Test® MCR-1).

With our renowned network, our rapid tests, fully developed and produced in France, are distributed worldwide in more than 70 countries and we have developed a proprietary patented immunoassay platform which can be tailored for your projects.

All our products are fully developed and produced in France, following the international quality standards.

QIAGEN serves more than 500,000 customers globally, all seeking insights from DNA, RNA and proteinsthe building blocks of life. Using any biological samplebe it blood, a throat swab or many other materialswe help our customers advance science and improve outcomes for people everywhere. Our products for molecular research and testing serve a wide range of applications from basic life sciences research to clinical healthcare. Together, we are making improvements in life possible. 

Discover more at

Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies.   

Selvita was established in 2007 and currently employs over 1000 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia. 

Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. If you want to learn more about our services, visit our website:

Amprologix specialises in antibiotic design and discovery. It is developing a portfolio of novel antibiotics derived from naturally occurring compounds. There is an urgent need for new antibiotics and the Amprologix team are experienced and committed to pioneering new solutions. They are using AI/machine learning tools to generate variants of their lead compound, epidermicin Nl01, which represents a new class of antibiotic drug with no known resistant liabilities. More details can be found at

Cellexus manufacture the only single use, airlift bioreactors available today. The CellMaker bioreactors have working volumes of 1.5L to 50L with the unique airlift system enabling excellent mixing and aeration without the shear stress. The CellMaker is designed to be versatile and has been proven for many applications. CellMaker achieve excellent results with bacteriophage amplification and bacterial biomass production, giving impressive yields. The CellMaker is a cost effective, low footprint, flexible alternative to other technologies while maintaining excellent performance.

Matoke is developing a non-pharmaceutical topical antimicrobial intervention, ready for clinical trial in 1 year and based on its patented Reactive Oxygen® technology. It has broad spectrum activity including against multi-drug resistant organisms, does not provoke the development of resistance and can avoid the unnecessary use of systemic antibiotics and contribute to antibiotic sparing. Therapeutics based on this technology bring the promise of being the next major breakthrough in acute, surgical and chronic wound management with an elegant manifestation of a naturally occurring mechanism.

OGI Bio ( gives users direct access to bacteria, yeast or algae so they can test their rapid diagnostics tests or novel mode of action quickly and reproducibly, accelerating innovation and increasing their speed to market. Our automated systems provide microbial cultures “on-tap” to all, removing the need for user-intervention in the culturing process through a low-cost, modular platform that sits on a user’s bench. The flexibility of our system allows you to measure parameters critical to your process (e.g. dissolved oxygen, pH, temperature) without having to pay for those that aren’t.

At OLM Diagnostics, our vision is to reduce illness and death associated with fungal disease globally; through use of rapid diagnostic testing and targeted, appropriate use of antimicrobials. Our mission is to make fungal diagnostic testing accessible on a global scale, by developing and providing rapid diagnostic kits that are robust, accurate and effective, yet inexpensive. Our novel and reliable rapid-diagnostic tests fit seamlessly into current treatment pathways, with the aim of reducing the rate of drug resistant infections by promoting a new diagnostic led approach. We aim to achieve this whilst delivering clear financial and clinical benefits to hospitals, clinicians and patient care.

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers and respiratory conditions. 

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,850 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”